Imricor Medical Systems (IMR) H1 2025 earnings summary

Executive summary

• Achieved CE Mark approval under MDR for second-generation ablation catheters, diagnostic catheters, capital equipment, and NorthStar 3D mapping system in Europe, and submitted Northstar for FDA approval with U.S. commercialization expected by year-end.

• Rebuilt and expanded the European sales team, increasing the hospital pipeline from 7 to 26 sites, and established Imricor BV in the Netherlands to accelerate R&D and commercialization.

• Revenue for H1 2025 was $196,875–$197,000, down 51.7%–52% year-over-year, mainly due to lower equipment sales and clinical trial recruitment.

• Net loss increased to $13.1 million, primarily due to fair value changes in convertible notes and warrants, with adjusted net loss (excluding fair value changes and FX) at $9.99–$10.0 million, up 26%–27% year-over-year.

• Maintains a strong balance sheet with $50.3 million cash at period end, bolstered by a $42.8–$44.1 million equity raise.

Financial highlights

• Total revenue for H1 2025 was $196,875–$197,000, down 51.7%–52% year-over-year, mainly due to lower equipment and capital sales.

• Consumable device sales were flat at $134,986–$135,000 compared to the prior period.

• Net loss after tax widened to $13.1 million, impacted by fair value changes in convertible notes and derivative liabilities.

• Adjusted net loss (excluding fair value changes and FX) was $9.99–$10.0 million, up 26%–27% year-over-year.

• Operating cash outflow for the half was $9.1 million, up year-over-year, with cash and cash equivalents at $50.3 million as of June 2025.

Outlook and guidance

• Expects Northstar FDA approval and U.S. commercial launch by year-end, with initial focus on pediatric hospitals and further site activations in the US, ANZ, Nordics, and Middle East within 6–24 months.

• Anticipates steady progress on regulatory submissions and approvals for additional devices through Q4 2025 and into early 2026.

• European and Middle Eastern commercial pipelines are maturing, with new site activations expected regularly through 2026.

• VT trial data in Europe expected to drive further adoption and support U.S. expansion.

• Management concluded that existing working capital is sufficient to fund operations for at least 12 months from the reporting date.